Table 1 Baseline characteristics whole cohort and stratified by donor type.
Group | Missing | Total | Mel200 | Vel-Mel | P | |
|---|---|---|---|---|---|---|
N (%) | N (%) | N (%) | ||||
Total | 4388 (100%) | 4096 (93.3%) | 292 (6.7%) | |||
Age at AHCT-1 | Median (IQR) | 58.9 (53–63.5) | 59 (53.3–63.5) | 56.8 (50.7–62.8) | <0.001 | |
Patient sex | Male | 2536 (57.8%) | 2366 (57.8%) | 170 (58.2%) | 0.928 | |
Female | 1852 (42.2%) | 1730 (42.2%) | 122 (41.8%) | |||
Karnofsky score | <90 | 285 (6.5%) | 1312 (32%) | 1252 (32.8%) | 60 (21.1%) | <0.001 |
90–100 | 2791 (68%) | 2566 (67.2%) | 225 (78.9%) | |||
ISS | I | 2235 (50.9%) | 926 (43.0%) | 857 (43.3%) | 69 (39.7%) | 0.504 |
II | 682 (31.7%) | 627 (31.7%) | 55 (31.6%) | |||
III | 545 (25.3%) | 495 (25.0%) | 50 (28.7%) | |||
Ig type | IgG | 1303 (29.7%) | 2229 (72.3%) | 2089 (72.7%) | 140 (66.7%) | <0.001 |
IgA | 751 (24.3%) | 698 (24.3%) | 53 (25.2%) | |||
IgD/M/E | 105 (3.4%) | 88 (3.1%) | 17 (8.1%) | |||
Cytogenetics | standard | 2799 (63.8%) | 1275 (80.2%) | 1202 (80.4%) | 73 (77.7%) | 0.607 |
high | 314 (19.8%) | 293 (19.6%) | 21 (22.3%) | |||
AHCT-1 year | Median (IQR) | 2014 (2012–2016) | 2014 (2012–2016) | 2014 (2012–2016) | 0.033 | |
Interval diagnosis AHCT-1 (months) | Median (IQR) | 33 (0.8%) | 6.3 (4.7–10.1) | 6.2 (4.7–9.9) | 7.7 (5.6–11.6) | 0.871 |
Bortezomib induction | no | 2943 (67.1%) | 213 (14.7%) | 193 (15.0%) | 20 (12.7%) | 0.507 |
yes | 1232 (85.3%) | 1094 (85.0%) | 138 (87.3%) | |||
Response at AHCT-1 | CR/VGPR | 53 (1.2%) | 939 (21.7%) | 822 (20.3%) | 117 (40.6%) | <0.001 |
<=PR | 1668 (38.5%) | 1602 (39.6%) | 66 (22.9%) | |||
1728 (39.9%) | 1623 (40.1%) | 105 (36.5%) | ||||
Response at d100 | CR/VGPR | 511 (16.4%) | 1533 (58.8%) | 1375 (57.7%) | 158 (70.2%) | <0.001 |
<=PR | 1074 (41.2%) | 1007 (42.3%) | 67 (29.8%) |
